Research map: SGLT2 Inhibitors in the Modern Cardiology Era: Mechanisms, Outcomes, and Clinical Applications

Back to the article

Papers in this map

  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes · Bernard Zinman · 2015 · 12293 citations · Cited by this paper
  2. Exosome Therapy: A Novel Investigational Approach in Acute Myocardial Infarction · 2026 · Related
  3. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction · John J.V. McMurray · 2019 · 7146 citations · Cited by this paper
  4. Beta-Blockers Versus Flecainide for Atrial Fibrillation: A First-Line Strategy Review of Efficacy, Safety, and Patient Selection · 2026 · Related
  5. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy · Vlado Perkovic · 2019 · 6222 citations · Cited by this paper
  6. Women in Heart Failure With Preserved Ejection Fraction Clinical Trials: Bridging the Gap Between Trial Enrollment and Real-World Disease Burden · 2026 · Related
  7. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure · Milton Packer · 2020 · 5221 citations · Cited by this paper
  8. Anesthetic-Electrophysiologic Interactions: How Sedatives Shape Cardiac Conduction and Arrhythmia Risk · 2026 · Related
  9. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials · Thomas A. Zelniker · 2018 · 2885 citations · Cited by this paper
  10. Cardiopulmonary Manifestations of Systemic Sclerosis: Pathophysiology, Clinical Presentation, and Management · 2026 · Related
  11. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction · Scott David Solomon · 2022 · 2871 citations · Cited by this paper
  12. Growing Heart Valves in Congenital Cardiac Surgery: Mechanisms and Considerations for Tissue-Engineered Heart Valves, Noncryopreserved Homografts, and Partial Heart Transplantation · 2026 · Related
  13. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure · Paul A. Heidenreich · 2022 · 2815 citations · Cited by this paper
  14. Impella Outcomes in Acute Myocardial Infarction Versus Non–Acute Myocardial Infarction Cardiogenic Shock: A United States Nationwide Propensity-Matched Analysis (2016–2022) · 2026 · Related
  15. Empagliflozin in Patients with Chronic Kidney Disease · The EMPA-KIDNEY Collaborative Group · 2022 · 2647 citations · Cited by this paper
  16. Chocolate and Cardiovascular Disease · 2026 · Related
  17. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure · Theresa A. McDonagh · 2023 · 2438 citations · Cited by this paper
  18. Pulmonary Hypertension and Kidney Disease: A Review of a High-Risk Patient Population · 2026 · Related
  19. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure · Deepak L. Bhatt · 2020 · 1873 citations · Cited by this paper
  20. Ranolazine: An Antiarrhythmic and Cardioprotective Agent · 2026 · Related
  21. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes · Nikolaus Marx · 2023 · 1602 citations · Cited by this paper
  22. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials · Faiez M. Zannad · 2020 · 1418 citations · Cited by this paper
  23. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus · David Z.I. Cherney · 2013 · 1331 citations · Cited by this paper
  24. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes · Darren K. McGuire · 2020 · 1248 citations · Cited by this paper
  25. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial · Adriaan A. Voors · 2022 · 936 citations · Cited by this paper
  26. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors · Gary D. Lopaschuk · 2020 · 908 citations · Cited by this paper
  27. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus · Thomas A. Zelniker · 2019 · 799 citations · Cited by this paper
  28. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease · Subodh Verma · 2019 · 592 citations · Cited by this paper
  29. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes · Mark Colquhoun Petrie · 2020 · 548 citations · Cited by this paper
  30. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction · Carlos G. Santos‐Gallego · 2020 · 548 citations · Cited by this paper
  31. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction · Milton Packer · 2020 · 442 citations · Cited by this paper
  32. Empagliflozin in Heart Failure · Matthew Dallas Griffin · 2020 · 419 citations · Cited by this paper
  33. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes · M Mercè Fernández‑Balsells · 2017 · 416 citations · Cited by this paper
  34. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association · Carmine Zoccali · 2023 · 363 citations · Cited by this paper
  35. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial · Erik J.M. van Bommel · 2019 · 359 citations · Cited by this paper
  36. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status · Stefan D. Anker · 2020 · 359 citations · Cited by this paper
  37. Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients · Mohsen Mazidi · 2017 · 356 citations · Cited by this paper
  38. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction · Pardeep S. Jhund · 2020 · 309 citations · Cited by this paper
  39. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction · Thomas M. Maddox · 2024 · 307 citations · Cited by this paper

Source: OpenAlex (CC0)